D-0657-2020 Class I Terminated

Recalled by Motto International Corp — Dallas, TX

FDA drug recall D-0657-2020 was initiated by Motto International Corp on Dec 17, 2019 and is designated Class I. Reason for recall: Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil The recall status is terminated (terminated Oct 29, 2021). Affected quantity: 1 box.

Recall details

Product Type
Drugs
Report Date
Jan 22, 2020
Initiation Date
Dec 17, 2019
Termination Date
Oct 29, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1 box

Product description

Panther Platinum 30000 Capsules, in green, black background with white, red text in hologram paper packaging, packaged in 2, 4, and 10 count blister cards, Motto International, Dallas, TX

Reason for recall

Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil

Distribution pattern

TX

Code information

All lots remaining within expiry.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0657-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0657-2020. Report a data issue: hello@regdatalab.com.